Novartis AG
Novartis is a high-quality pharma compounder, but at 21.41x earnings with FY26 core operating income guided down low single digits and one-time Q2 benefits reversing in H2, the current setup looks balanced rather than mispriced.
Novartis is not a broken story. It is a high-quality pharma franchise moving through an awkward earnings valley while trying to prove that its next generation of assets can carry the P&L. That distinction matters at $143.29. The business still shows real operating strength, with FY2025 revenue of $54.8B, up 9.7%, and operating margin up to 29.8% from 28.1%. The priority-brand engine is clearly working at the product level, with that basket up 36% cc, and KISQALI now producing more than $1B in U.S. quarterly sales. Those are not the numbers of a deteriorating franchise.
The problem is that investors do not own only the product story, they own the earnings bridge. And right now that bridge is messy. FY2025 EPS fell 18.7% to $7.25 despite good revenue growth. For FY26, management is not promising a clean rebound. It is guiding low single-digit net sales growth and a low single-digit decline in core operating income for the full year. Q2 looked better on the surface, but management also disclosed that phasing added roughly 1 point to sales and 5 points to core operating income, both reversing in H2. That makes the October print especially important because the market needs proof that underlying demand and mix can carry the second half without temporary help.
Valuation is fair, not cheap enough to absorb much disappointment. At 21.41x P/E, Novartis trades below the 28.6x peer average, but peer dispersion is wide and includes names with structurally different growth profiles. The company also carries $49.0B of debt, Debt/EBITDA of 2.13, and a current ratio of 0.86, so this is not the kind of fortress balance sheet that invites aggressive multiple expansion in a 4.96% 10-year Treasury world. The right case for owning it is patience into 2027 earnings power, not a near-term rerating.
The case depends on three things. First, growth brands must keep compounding fast enough to offset mature-brand erosion. Second, H2 2026 must validate management's guided step-up after reversing Q2 phasing benefits. Third, pipeline readouts such as pelacarsen, remibrutinib and ianalumab need to support confidence in the 3 to 5 year moat. Until that evidence is firmer, HOLD is the disciplined call.
KISQALI and other priority brands sustain outsized growth, pipeline readouts land well, and investors underwrite 2027 earnings power closer to the high end of management's medium-term margin ambitions.
Growth brands continue to offset erosion, H2 improves as guided, and valuation holds near current levels with modest upside from normalized earnings visibility.
H2 phasing reversal, Entresto/generic pressure, and weaker pipeline conversion keep earnings flat to down and compress the stock toward a lower-teens pharma multiple.
Quant call aligns with analyst consensus (Hold: 0 buy / 1 hold / 0 sell).
It never was my thinking that made the big money for me. It always was my sitting.
Forward earnings power is still in reset mode, not acceleration mode. The trailing 21.41x P/E looks reasonable against peers, but the right lens is that management is guiding FY26 core operating income down low single digits before a hoped-for H2 improvement, so the market is already paying for a better 2027 than 2026. The moat remains real over the next 3 to 5 years because Novartis still has branded scale, oncology and immunology depth, and a broad late-stage pipeline, but durability now depends more on replacing erosion with assets like KISQALI, Scemblix, LEQVIO, Kesimpta and PLUVICTO than on legacy blockbusters. AI is a modest advantage rather than a thesis-changing one here, helpful for discovery, trial design and productivity, but not enough to overcome regulation, patent cliffs, China pricing pressure in Cosentyx, and manufacturing complexity in radioligand and biologic launches.
- Priority brands grew 36% cc, led by KISQALI, Scemblix, LEQVIO, Kesimpta and PLUVICTO, supporting medium-term replacement of mature products.
- FY2025 revenue rose 9.7% to $54.8B and operating margin improved to 29.8% from 28.1%, showing the core franchise still converts growth into profit.
- FY26 guidance remains muted, with management expecting low single-digit net sales growth and low single-digit decline in core operating income, which caps near-term re-rating.
- Q2 2026 revenue returned to growth, up 1% cc to $14.4B, faster than initially expected, with EBITDA of $5.94B at a 41.2% margin.
- KISQALI U.S. sales exceeded $1B in a quarter for the first time, and management kept the $10B peak sales target, a material earnings-power driver if execution holds.
- Valuation is not stretched for a large-cap quality pharma name, with P/E 21.41 versus peer average 28.6 and P/S 4.88 versus 5.0 for peers.
- Capital returns remain active, with $5.6B of buyback authorization still in place through end-2027, alongside $2.9B of dividends and only $0.3B of capex.
- FY2025 EPS fell 18.7% to $7.25 despite revenue growth, a reminder that sales growth is not translating cleanly into per-share earnings yet.
- Management explicitly said, "we are reaffirming our full year guidance for 2026," not raising it, even after Q2 recovered faster than expected.
- Q2 had temporary help, with approximately 1 percentage point benefit to sales and about 5 percentage points benefit to core operating income from phasing that reverses in H2.
- Balance-sheet flexibility is only fair, not strong, with Debt/EBITDA 2.13, Debt/Equity 1.18, and a current ratio of 0.86, while FCF was $5.6B against $49.0B of total debt.
| Metric | Value | Context |
|---|---|---|
| Current price | $143.29 | Reference price for valuation and scenario framing |
| Quant price target | $157.05 | Implies 9.6% upside, Medium confidence, basis: earnings_growth_blend |
| FY2025 revenue | $54.8B | +9.7% YoY, solid sales growth despite transition year |
| FY2025 EPS | $7.25 | -18.7% YoY, key reason the near-term story is less clean than revenue suggests |
| Operating margin | 29.8% | Up from 28.1% in the prior FY, showing underlying cost discipline |
| Net margin | 24.3% | Strong absolute profitability for large-cap pharma |
| P/E | 21.41 | Below peer avg 28.6, but peer set has WIDE dispersion 5.5x |
| P/S | 4.88 | Slightly below peer avg 5.0, close to fair value on sales |
| Debt/EBITDA | 2.13 | Manageable, but not light given $49.0B total debt |
| FCF | $5.6B | Supports dividends and buybacks, but modest relative to debt load |
| FY26 guidance | Net sales low single-digit growth, core operating income low single-digit decline | Reaffirmed, not raised, despite Q2 recovery |
| 52-week position | -15.9% vs high, -4.7% below 200-day average | Shares have pulled back from $170.46 but are not washed out |
The biggest risk is that the growth-brand ramp fails to offset mature-product erosion fast enough, because FY26 already assumes only low single-digit sales growth and a low single-digit decline in core operating income.
The next clear catalyst is Q3 earnings on October 27, 2026, when investors will test whether H2 can actually deliver the guided mid-single-digit sales growth after reversing Q2 phasing benefits and absorbing the $800M prior-year Entresto comparison base.
Ownership looks stable and not crowded, with the top three institutions holding only 7.2% combined and insiders at 0.0%. Short interest is very low at 0.31% of shares, or 5.6M shares and 2.9 days to cover, which argues against a squeeze setup. Options positioning is less supportive near term, with negative gamma and a zero-gamma level at $147.08, above spot, which can amplify moves until the stock reclaims that zone.
Growth is being driven by priority brands including KISQALI, Scemblix, LEQVIO, Kesimpta and PLUVICTO, which grew 36% cc in aggregate.
U.S. momentum is important, with KISQALI U.S. sales above $1B in a quarter, but H2 comparisons are skewed by $800M of prior-year Q3 Entresto base.
A pressure point due to Cosentyx competition, showing geographic exposure matters even when global brand performance is holding up.
PLUVICTO expansion and manufacturing build-out support future mix improvement, but execution is operationally heavier than a standard small-molecule launch.
Novartis reaffirmed FY26 as Q2 returned to sales growth faster than expected.
Management looks credible, but not infallible. In the 2024 Q2 call, Novartis was strong enough to raise guidance and said, "Taken together, this allowed us to upgrade our full year 2024 core operating income guidance," while reporting Q2 sales +11% CC and core operating income +19%. Since then, execution has been mixed but still decent: FY2025 revenue reached $54.8B, up 9.7%, and operating margin improved to 29.8% from 28.1%, but FY2025 EPS fell 18.7% to $7.25, and FY26 guidance is now much softer, with management saying, "We continue to expect net sales to grow low single digits and core operating income to decline low single digits for the full year." On product timelines, they flagged in 2024 that remibrutinib filing shifted to 2025, and in 2026 H2 it remains a key expected readout or approval, so the pipeline is moving, but not without slippage. The beat-miss record is also mixed recently, with Q2 2026 EPS beat by 11.1% after a Q1 2026 miss of 5.7%.
we are reaffirming our full year guidance for 2026.
We continue to expect net sales to grow low single digits and core operating income to decline low single digits for the full year.
Turning to H2, we continue to expect net sales to grow mid-single digits as we move beyond the impact of U.S. generic erosion. We expect H2 core operating income to grow mid to high single digits with continued investment in our growth drivers as well as our R&D pipeline.
The strong performance of priority brands supported a return to net sales growth in quarter two faster than we initially expected.
Worth to note that Q2 results were also positively impacted by some one-time phasing items, which will reverse in the second half. Together, these items positively impacted net sales by approximately one percentage point and core operating income by about five percentage points.
Novartis is protected by scale in branded prescription drugs, deep regulatory and commercialization capabilities, and a portfolio concentrated in difficult therapeutic areas like oncology, immunology and specialty medicines. The moat is durable, but less effortless than it looked a few years ago because the company is now proving that newer brands can replace mature-product erosion at scale. The strongest proof point is the 36% cc growth of the priority-brand basket and KISQALI crossing $1B in quarterly U.S. sales.
Capital allocation is broadly disciplined but not pristine. In the latest cash flow snapshot, Novartis generated $5.6B of FCF, spent only $0.3B on capex, returned $2.9B via dividends and $1.2B via buybacks, and still has $5.6B left on the repurchase program through end-2027. The question is not willingness to return cash, it is whether that return pace should be more conservative given $49.0B of debt and only moderate financial-health metrics.
Rated HOLD, Medium conviction. Novartis still owns a real growth engine in its priority brands, and the stock is not expensive on simple multiples, but the market is already looking past a weak FY26 and asking investors to trust a better 2027. That is a reasonable stance for existing holders, not an obvious setup for aggressive new buying today. A move to BUY would require either a more meaningful valuation dislocation or proof in upcoming quarters that H2 growth and pipeline conversion are strong enough to lift forward earnings cleanly. A move to SELL would require evidence that growth brands are no longer offsetting mature-brand erosion and that the earnings bridge is slipping again.
≣ Full research note tap to expand
Executive Summary
HOLD, Medium conviction. NVS rates a HOLD at Medium conviction. The business still has real strengths, including 29.8% operating margin, a deep bench of growth brands growing 36% cc, and credible medium-term assets, but the stock sits in a transition year where FY26 sales are only guided to low single-digit growth and Q2 benefited from about 1 point of sales and 5 points of core operating income phasing that reverses in H2. At $143.29, with a quant base target of $157.05 and the shares still only 15.9% below the 52-week high, upside exists but is not wide enough for a stronger call given execution and balance-sheet constraints.
Investment Thesis
Novartis is not a broken story. It is a high-quality pharma franchise moving through an awkward earnings valley while trying to prove that its next generation of assets can carry the P&L. That distinction matters at $143.29. The business still shows real operating strength, with FY2025 revenue of $54.8B, up 9.7%, and operating margin up to 29.8% from 28.1%. The priority-brand engine is clearly working at the product level, with that basket up 36% cc, and KISQALI now producing more than $1B in U.S. quarterly sales. Those are not the numbers of a deteriorating franchise.
The problem is that investors do not own only the product story, they own the earnings bridge. And right now that bridge is messy. FY2025 EPS fell 18.7% to $7.25 despite good revenue growth. For FY26, management is not promising a clean rebound. It is guiding low single-digit net sales growth and a low single-digit decline in core operating income for the full year. Q2 looked better on the surface, but management also disclosed that phasing added roughly 1 point to sales and 5 points to core operating income, both reversing in H2. That makes the October print especially important because the market needs proof that underlying demand and mix can carry the second half without temporary help.
Valuation is fair, not cheap enough to absorb much disappointment. At 21.41x P/E, Novartis trades below the 28.6x peer average, but peer dispersion is wide and includes names with structurally different growth profiles. The company also carries $49.0B of debt, Debt/EBITDA of 2.13, and a current ratio of 0.86, so this is not the kind of fortress balance sheet that invites aggressive multiple expansion in a 4.96% 10-year Treasury world. The right case for owning it is patience into 2027 earnings power, not a near-term rerating.
The case depends on three things. First, growth brands must keep compounding fast enough to offset mature-brand erosion. Second, H2 2026 must validate management's guided step-up after reversing Q2 phasing benefits. Third, pipeline readouts such as pelacarsen, remibrutinib and ianalumab need to support confidence in the 3 to 5 year moat. Until that evidence is firmer, HOLD is the disciplined call.
Key Metrics
| Metric | Value | Context |
|---|---|---|
| Current price | $143.29 | Reference price for valuation and scenario framing |
| Quant price target | $157.05 | Implies 9.6% upside, Medium confidence, basis: earnings_growth_blend |
| FY2025 revenue | $54.8B | +9.7% YoY, solid sales growth despite transition year |
| FY2025 EPS | $7.25 | -18.7% YoY, key reason the near-term story is less clean than revenue suggests |
| Operating margin | 29.8% | Up from 28.1% in the prior FY, showing underlying cost discipline |
| Net margin | 24.3% | Strong absolute profitability for large-cap pharma |
| P/E | 21.41 | Below peer avg 28.6, but peer set has WIDE dispersion 5.5x |
| P/S | 4.88 | Slightly below peer avg 5.0, close to fair value on sales |
| Debt/EBITDA | 2.13 | Manageable, but not light given $49.0B total debt |
| FCF | $5.6B | Supports dividends and buybacks, but modest relative to debt load |
| FY26 guidance | Net sales low single-digit growth, core operating income low single-digit decline | Reaffirmed, not raised, despite Q2 recovery |
| 52-week position | -15.9% vs high, -4.7% below 200-day average | Shares have pulled back from $170.46 but are not washed out |
Financial Strength
The balance sheet is adequate, not a differentiator. Profitability is excellent, with a 29.8% operating margin and a perfect 100 profitability sub-score, and capex needs are light at $0.3B, which helps cash conversion. But financial flexibility is held back by $49.0B of debt, Debt/Equity of 1.18, Debt/EBITDA of 2.13, and a current ratio of 0.86, which is why the financial-health sub-score sits at only 38. Novartis can fund R&D, dividends, and buybacks, but it does not have the excess balance-sheet room that would make a weaker earnings year easy to ignore.
Competitive Position
Novartis is protected by scale in branded prescription drugs, deep regulatory and commercialization capabilities, and a portfolio concentrated in difficult therapeutic areas like oncology, immunology and specialty medicines. The moat is durable, but less effortless than it looked a few years ago because the company is now proving that newer brands can replace mature-product erosion at scale. The strongest proof point is the 36% cc growth of the priority-brand basket and KISQALI crossing $1B in quarterly U.S. sales.
Management & Guidance
Management's current message is measured and credible, but not especially bullish. The most important line from the Q2 2026 call was, "we are reaffirming our full year guidance for 2026," alongside CFO commentary that the company still expects low single-digit sales growth and a low single-digit decline in core operating income for the full year. That caution is believable because management also disclosed the temporary phasing lift in Q2 and the $800M Entresto comparison distortion in Q3. The guidance is therefore transparent, but the fact pattern does not justify paying ahead for a strong FY26 acceleration unless H2 data confirms the improvement.
Segment Analysis
- Innovative Medicines (Primary business, exact FY2025 split not provided): Growth is being driven by priority brands including KISQALI, Scemblix, LEQVIO, Kesimpta and PLUVICTO, which grew 36% cc in aggregate.
- United States (Largest profit pool, exact share not provided): U.S. momentum is important, with KISQALI U.S. sales above $1B in a quarter, but H2 comparisons are skewed by $800M of prior-year Q3 Entresto base.
- China (Material market, exact share not provided): A pressure point due to Cosentyx competition, showing geographic exposure matters even when global brand performance is holding up.
- Radioligand and specialty pipeline markets (Emerging growth contribution): PLUVICTO expansion and manufacturing build-out support future mix improvement, but execution is operationally heavier than a standard small-molecule launch.
Capital Allocation
Capital allocation is broadly disciplined but not pristine. In the latest cash flow snapshot, Novartis generated $5.6B of FCF, spent only $0.3B on capex, returned $2.9B via dividends and $1.2B via buybacks, and still has $5.6B left on the repurchase program through end-2027. The question is not willingness to return cash, it is whether that return pace should be more conservative given $49.0B of debt and only moderate financial-health metrics.
Management Execution & Track Record
Management looks credible, but not infallible. In the 2024 Q2 call, Novartis was strong enough to raise guidance and said, "Taken together, this allowed us to upgrade our full year 2024 core operating income guidance," while reporting Q2 sales +11% CC and core operating income +19%. Since then, execution has been mixed but still decent: FY2025 revenue reached $54.8B, up 9.7%, and operating margin improved to 29.8% from 28.1%, but FY2025 EPS fell 18.7% to $7.25, and FY26 guidance is now much softer, with management saying, "We continue to expect net sales to grow low single digits and core operating income to decline low single digits for the full year." On product timelines, they flagged in 2024 that remibrutinib filing shifted to 2025, and in 2026 H2 it remains a key expected readout or approval, so the pipeline is moving, but not without slippage. The beat-miss record is also mixed recently, with Q2 2026 EPS beat by 11.1% after a Q1 2026 miss of 5.7%.
Positioning & Flows
Ownership looks stable and not crowded, with the top three institutions holding only 7.2% combined and insiders at 0.0%. Short interest is very low at 0.31% of shares, or 5.6M shares and 2.9 days to cover, which argues against a squeeze setup. Options positioning is less supportive near term, with negative gamma and a zero-gamma level at $147.08, above spot, which can amplify moves until the stock reclaims that zone.
Bull Case
- Q2 2026 revenue returned to growth, up 1% cc to $14.4B, faster than initially expected, with EBITDA of $5.94B at a 41.2% margin.
- KISQALI U.S. sales exceeded $1B in a quarter for the first time, and management kept the $10B peak sales target, a material earnings-power driver if execution holds.
- Valuation is not stretched for a large-cap quality pharma name, with P/E 21.41 versus peer average 28.6 and P/S 4.88 versus 5.0 for peers.
- Capital returns remain active, with $5.6B of buyback authorization still in place through end-2027, alongside $2.9B of dividends and only $0.3B of capex.
Bear Case
- FY2025 EPS fell 18.7% to $7.25 despite revenue growth, a reminder that sales growth is not translating cleanly into per-share earnings yet.
- Management explicitly said, "we are reaffirming our full year guidance for 2026," not raising it, even after Q2 recovered faster than expected.
- Q2 had temporary help, with approximately 1 percentage point benefit to sales and about 5 percentage points benefit to core operating income from phasing that reverses in H2.
- Balance-sheet flexibility is only fair, not strong, with Debt/EBITDA 2.13, Debt/Equity 1.18, and a current ratio of 0.86, while FCF was $5.6B against $49.0B of total debt.
Valuation & Price Target
Engine price target $157.05 (+9.6% vs current), Medium confidence.
- P/E Multiple: $176.64 (28% weight)
- PEG (growth-adjusted): $96.9 (20% weight)
- P/S Multiple: $162.14 (20% weight)
- Quality-adjusted: $161.63 (20% weight)
- DCF: $239.07 (6% weight)
The rating stays aligned with the quant baseline HOLD. The engine's $157.05 target implies 9.6% upside, but that is only moderate for a stock with wide peer P/E dispersion of 5.5x, a quality score of 66/100, a risk score of 49/100, and management guiding low single-digit sales growth with a low single-digit core operating income decline for FY26. A more bullish stance would need either a cleaner earnings trajectory, better balance-sheet comfort than Debt/EBITDA 2.13, or a larger valuation discount. Sell-side consensus is also Hold, but with only 1 firm it is low-signal context, not a pillar of the call.
Risk Assessment
Risk score 49/100 (Moderate). The biggest risk is that the growth-brand ramp fails to offset mature-product erosion fast enough, because FY26 already assumes only low single-digit sales growth and a low single-digit decline in core operating income.
The Bottom Line
Rated HOLD, Medium conviction. Novartis still owns a real growth engine in its priority brands, and the stock is not expensive on simple multiples, but the market is already looking past a weak FY26 and asking investors to trust a better 2027. That is a reasonable stance for existing holders, not an obvious setup for aggressive new buying today. A move to BUY would require either a more meaningful valuation dislocation or proof in upcoming quarters that H2 growth and pipeline conversion are strong enough to lift forward earnings cleanly. A move to SELL would require evidence that growth brands are no longer offsetting mature-brand erosion and that the earnings bridge is slipping again.
Go deeper in the app
Live charts, options analytics, the full earnings-call breakdown, price alerts, and every other stock — updated in real time.
Get Tickr